In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at ...

Biogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.

Hilary Evans-Newton is the Chief Executive of Alzheimer’s Research UK. Hilary joined Alzheimer’s Research UK in 2013 and has overseen significant growth in income in recent years, which has ...

A revolutionary gene therapy treatment costing a staggering £1.65 million has been approved for NHS use, offering patients ...

If your loved one experiences sudden cognitive decline, they may be experiencing a rare type of dementia called rapidly progressive dementia.

Drugs targeting amyloid plaques have failed to show efficacy in clinical trials. A new approach is needed to tackle AD ...

Why the once-stigmatized treatment is back for women under 60.

Alzheimer's disease, a devastating neurodegenerative condition that impacts millions globally, may have found an unexpected ...

When someone with dementia loses their ability to have empathy, caring for them can become isolating and fraught, research ...

Access to the new Alzheimer's drugs is limited by strict eligibility criteria, long wait times, and a lack of infusion ...

The FDA has approved the sBLA of Eisai and Biogen's LEQEMBI for maintenance dosing indicated for the early stages of ...

Lecanemab is a humanized immunoglobulin gamma 1 monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta.